购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • Others
    (4)
TargetMol | Tags 通过 货期 筛选
  • 现货
    (2)
  • 5日内发货
    (3)
  • 20日内发货
    (1)
  • 35日内发货
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "m-133"的结果
筛选
搜索结果
TargetMol产品目录中 "

m-133

"的结果
  • 抑制剂&激动剂
    6
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    4
    TargetMol | Recombinant_Protein
  • 同位素
    1
    TargetMol | Isotope_Products
  • M133
    T698832127411-61-2
    M133 is a selective histone deacetylase HDAC1 and HDAC2 inhibitor and potent antitumor agent.
    • ¥ 10600
    6-8周
    规格
    数量
  • Pefabloc
    T698822131171-67-8
    Pefabloc is an irreversible serine proteinase inhibitor. Pefabloc efficiently inhibits both human and rat platelet activating factor (PAF)-degrading acetylhydrolase (acetylhydrolase).
    • ¥ 27790
    6-8周
    规格
    数量
  • UCM-1336
    3,3′-(Octylimino)bis[N-phenylpropanamide]
    T99351621535-90-7In house
    UCM-1336 (3,3′-(Octylimino)bis[N-phenylpropanamide]) 是一种有效的 ICMT 抑制剂,IC50 为 2 μM,对参与 Ras 翻译后修饰的其他酶具有选择性。
    • ¥ 186
    In stock
    规格
    数量
    TargetMol | Inhibitor Sale
  • RM-133
    RM133
    T34335
    RM-133 is a promising pro-apoptotic agent which shows activity on various cancer cell lines.
    • 待询
    规格
    数量
  • UCM-13369
    T875912921944-77-4
    UCM-13369 (Compound 4b) 作为一种NPM1抑制剂,它能特异性地针对 NPM1 C+ 的 C 端 DNA 结合域,并下调其相关信号通路。此外,UCM-13369 还能诱导 AML 细胞系与原代细胞的凋亡,对于AML的研究具有重要用途。
    • 待询
    10-14周
    规格
    数量
  • Nitisinone-13C6
    Nitisinone-13C6
    T360551246815-63-3
    Nitisinone-13C6is intended for use as an internal standard for the quantification of nitisinone by GC- or LC-MS. Nitisinone is an inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD), which converts 4-hydroxyphenylpyruvate (HPPA) to homogentisate in the tyrosine catabolic pathway.1Nitisinone increases urinary levels of HPPA and 4-hydroxyphenyllactate (HPLA) in rats when administered at a dose of 10 mg kg. Nitisinone (3 mg kg) prevents the neonatal lethality of fumarylacetoacetate hydrolase (FAH) deficiency in mice when administered to pregnant dams.2It exhibits hepatoprotective effects inFAH- -mice, such as prevention of increases in plasma levels of aspartate serine aminotransferase (AST) and conjugated bilirubin, when administration is continued following birth at a dose of 1 mg kg. Nitisinone (100 μg) decreases urinary excretion of homogentisate and increases urinary excretion of HPPA, HPLA, and 4-hydroxyphenylacetate in a mouse model of alkaptonuria induced by ethylnitrosourea.3Formulations containing nitisinone have been used in the treatment of hereditary tyrosinemia type 1 (HT-1). 1.Ellis, M.K., Whitfield, A.C., Gowans, L.A., et al.Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dioneToxicol. Appl. Pharmacol.133(1)12-19(1995) 2.Grompe, M., Lindstedt, S., al-Dhalimy, M., et al.Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type INat. Genet.10(4)453-460(1995) 3.Suzuki, Y., Oda, K., Yoshikawa, Y., et al.A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuriaJ. Hum. Genet.44(2)79-84(1999)
    • ¥ 6930
    35日内发货
    规格
    数量